UGT1A1 gene polymorphisms and the toxicities of FOLFIRI in Chinese Han patients with gastrointestinal cancer

Anti-Cancer Agents in Medicinal Chemistry

Volumn 13, Issue 2, 2013, Pages 235-241

  Zhou, Chen fei ^a   Ma, Tao ^a   Su, Yang ^a   Ye, Zheng bao ^a   Ji, Jun ^a   Yu, Ying yan ^a   Zhang, Jun ^a   Liu, Bing ya ^a   Zhu, Zheng gang ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Gastrointestinal cancer; Irinotecan; Molecular diagnosis; Predictive marker; UGT1A1 polymorphism

Indexed keywords

ATROPINE; BILIRUBIN; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; SEROTONIN 3 ANTAGONIST;

ADULT; AGED; ARTICLE; CANCER INCIDENCE; CONTINUOUS INFUSION; DIARRHEA; DIGESTIVE SYSTEM CANCER; DISEASE COURSE; DNA POLYMORPHISM; DNA SEQUENCE; DRUG WITHDRAWAL; FEMALE; GENE FREQUENCY; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASIAN CONTINENTAL ANCESTRY GROUP; DIARRHEA; GASTROINTESTINAL NEOPLASMS; GLUCURONOSYLTRANSFERASE; HUMANS; POLYMORPHISM, GENETIC;

EID: 84876711885     PISSN: 18715206     EISSN: 18755992     Source Type: Journal    
DOI: 10.2174/1871520611313020008     Document Type: Article

References (33)

1. Yang, L.; Parkin, D.M.; Ferlay, J.; Li, L.; Chen, Y. Estimates of cancer incidence in China for 2000 and projections for 2005. Cancer Epidemiol. Biomarkers Prev., 2005, 14(1), 243-250.
2. Rosner, G.L.; Panetta, J.C.; Innocenti, F.; Ratain, M.J. Pharma- cogenetic pathway analysis of irinotecan. Clin. Pharmacol. Ther., 2008, 84(3), 393-402.
3. Tournigand, C.; Andre, T.; Achille, E.; Lledo, G.; Flesh, M.; Mery-Mignard, D.; Quinaux, E.; Couteau, C.; Buyse, M.; Ganem, G.; Landi, B.; Colin, P.; Louvet, C.; de Gramont, A. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J. Clin. Oncol., 2004, 22(2), 229-237.
4. Conroy, T.; Desseigne, F.; Ychou, M.; Bouche, O.; Guimbaud, R.; Becouarn, Y.; Adenis, A.; Raoul, J.L.; Gourgou-Bourgade, S.; de la Fouchardiere, C.; Bennouna, J.; Bachet, J.B.; Khemissa-Akouz, F.; Pere-Verge, D.; Delbaldo, C.; Assenat, E.; Chauffert, B.; Michel, P.; Montoto-Grillot, C.; Ducreux, M. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N. Engl. J. Med., 2011, 364(19), 1817-1825.
5. Seo, M.D.; Lee, K.W.; Lim, J.H.; Yi, H.G.; Kim, D.Y.; Oh, D.Y.; Kim, J.H.; Im, S.A.; Kim, T.Y.; Lee, J.S.; Bang, Y.J. Irinotecan combined with 5-fluorouracil and leucovorin as second-line chemotherapy for metastatic or relapsed gastric cancer. Jpn. J. Clin. Oncol., 2008, 38(9), 589-595.
6. Marsh, S.; Hoskins, J.M. Irinotecan pharmacogenomics. Pharma-cogenomics, 2010, 11(7), 1003-1010.
7. Ando, M.; Hasegawa, Y.; Ando, Y. Pharmacogenetics of irinotecan: a promoter polymorphism of UGT1A1 gene and severe adverse reactions to irinotecan. Invest. New Drugs, 2005, 23(6), 539-545.
8. Nagar, S.; Blanchard, R.L. Pharmacogenetics of uridine diphosphoglucuronosyltransferase (UGT) 1A family members and its role in patient response to irinotecan. Drug Metab. Rev., 2006, 38(3), 393-409.
9. Palomaki, G.E.; Bradley, L.A.; Douglas, M.P.; Kolor, K.; Dotson, W.D. Can UGT1A1 genotyping reduce morbidity and mortality in patients with metastatic colorectal cancer treated with irinotecan? An evidence-based review. Genet. Med., 2009, 11(1), 21-34.
10. Zhang, A.; Xing, Q.; Qin, S.; Du, J.; Wang, L.; Yu, L.; Li, X.; Xu, L.; Xu, M.; Feng, G.; He, L. Intra-ethnic differences in genetic variants of the UGT-glucuronosyltransferase 1A1 gene in Chinese populations. Pharmacogenomics J., 2007, 7(5), 333-338.
11. Innocenti, F.; Kroetz, D.L.; Schuetz, E.; Dolan, M.E.; Ramirez, J.; Relling, M.; Chen, P.; Das, S.; Rosner, G.L.; Ratain, M.J. Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics. J. Clin. Oncol., 2009, 27(16), 2604-2614.
12. Oken, M.M.; Creech, R.H.; Tormey, D.C.; Horton, J.; Davis, T.E.; McFadden, E.T.; Carbone, P.P. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am. J. Clin. Oncol., 1982, 5(6), 649-655.
13. Common Terminology Criteria for Adverse Events, Version 3.0. Cancer Therapy Evaluation Program, 2006.
14. Therasse, P.; Arbuck, S.G.; Eisenhauer, E.A.; Wanders, J.; Kaplan, R.S.; Rubinstein, L.; Verweij, J.; Van Glabbeke, M.; van Oosterom, A.T.; Christian, M.C.; Gwyther, S.G. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J. Natl. Cancer Inst., 2000, 92(3), 205-216.
15. Han, J.Y.; Lim, H.S.; Shin, E.S.; Yoo, Y.K.; Park, Y.H.; Lee, J.E.; Jang, I.J.; Lee, D.H.; Lee, J.S. Comprehensive analysis of UGT1A polymorphisms predictive for pharmacokinetics and treatment outcome in patients with non-small-cell lung cancer treated with irinotecan and cisplatin. J. Clin. Oncol., 2006, 24(15), 2237-2244.
16. Cecchin, E.; Innocenti, F.; D'Andrea, M.; Corona, G.; De Mattia, E.; Biason, P.; Buonadonna, A.; Toffoli, G. Predictive role of the UGT1A1, UGT1A7, and UGT1A9 genetic variants and their haplotypes on the outcome of metastatic colorectal cancer patients treated with fluorouracil, leucovorin, and irinotecan. J. Clin. Oncol., 2009, 27(15), 2457-2465.
17. Liu, C.Y.; Chen, P.M.; Chiou, T.J.; Liu, J.H.; Lin, J.K.; Lin, T.C.; Chen, W.S.; Jiang, J.K.; Wang, H.S.; Wang, W.S. UGT1A1*28 polymorphism predicts irinotecan-induced severe toxicities without affecting treatment outcome and survival in patients with metastatic colorectal carcinoma. Cancer, 2008, 112(9), 1932-1940.
18. Wang, Y.; Xu, J.M.; Shen, L.; Xu, N.; Wang, J.W.; Jiao, S.C.; Zhang, J.S.; Song, S.T.; Li, J.; Bao, H.Y.; Yang, L.; Li, F. [Polymorphisms of UGT1A gene and irinotecan toxicity in Chinese colorectal cancer patients]. Zhonghua Zhong Liu Za Zhi, 2007, 29(12), 913-916.
19. Onoue, M.; Terada, T.; Kobayashi, M.; Katsura, T.; Matsumoto, S.; Yanagihara, K.; Nishimura, T.; Kanai, M.; Teramukai, S.; Shimizu, A.; Fukushima, M.; Inui, K. UGT1A1*6 polymorphism is most predictive of severe neutropenia induced by irinotecan in Japanese cancer patients. Int. J. Clin. Oncol., 2009, 14(2), 136-142.
20. Okuyama, Y.; Hazama, S.; Nozawa, H.; Kobayashi, M.; Takahashi, K.; Fujikawa, K.; Kato, T.; Nagata, N.; Kimura, H.; Oba, K.; Sakamoto, J.; Mishima, H. Prospective phase II study of FOLFIRI for mCRC in Japan, including the analysis of UGT1A1 28/6 polymorphisms. Jpn. J. Clin. Oncol., 2011, 41(4), 477-482.
21. Jada, S.R.; Lim, R.; Wong, C.I.; Shu, X.; Lee, S.C.; Zhou, Q.; Goh, B.C.; Chowbay, B. Role of UGT1A1*6, UGT1A1*28 and ABCG2 c.421C>A polymorphisms in irinotecan-induced neutropenia in Asian cancer patients. Cancer Sci., 2007, 98(9), 1461-1467.
22. Cote, J.F.; Kirzin, S.; Kramar, A.; Mosnier, J.F.; Diebold, M.D.; Soubeyran, I.; Thirouard, A.S.; Selves, J.; Laurent-Puig, P.; Ychou, M. UGT1A1 polymorphism can predict hematologic toxicity in patients treated with irinotecan. Clin. Cancer Res., 2007, 13(11), 3269-3275.
23. Hu, Z.Y.; Yu, Q.; Pei, Q.; Guo, C. Dose-dependent association between UGT1A1*28 genotype and irinotecan-induced neutropenia: low doses also increase risk. Clin. Cancer Res., 2010, 16(15), 3832-3842.
24. Li, J.; Liu, X.; Wang, B.Y.; Guo, W.J.; Yin, J.L.; Zhu, X.D.; Zhang, J.; Liu, T. Phase II study of cetuximab in combination with modified FOLFIRI in patients with advanced gastric cancer who failed first-line chemotherapy (EFFI study). J. Clin. Oncol., 2010, 28(15s), suppl; abstr 4107.
25. Minami, H.; Sai, K.; Saeki, M.; Saito, Y.; Ozawa, S.; Suzuki, K.; Kaniwa, N.; Sawada, J.; Hamaguchi, T.; Yamamoto, N.; Shirao, K.; Yamada, Y.; Ohmatsu, H.; Kubota, K.; Yoshida, T.; Ohtsu, A.; Saijo, N. Irinotecan pharmacokinetics/pharmacodynamics and UGT1A genetic polymorphisms in Japanese: roles of UGT1A1*6 and *28. Pharmacogenet. Genomics, 2007, 17(7), 497-504.
26. Sai, K.; Saito, Y.; Sakamoto, H.; Shirao, K.; Kurose, K.; Saeki, M.; Ozawa, S.; Kaniwa, N.; Hirohashi, S.; Saijo, N.; Sawada, J.; Yoshida, T. Importance of UDP-glucuronosyltransferase 1A1*6 for irinotecan toxicities in Japanese cancer patients. Cancer Lett., 2008, 261(2), 165-171.
27. Fang, J.L.; Lazarus, P. Correlation between the UDP-glucuronosyltransferase (UGT1A1) TATAA box polymorphism and carcinogen detoxification phenotype: significantly decreased glucuronidating activity against benzo(a)pyrene-7,8-dihydrodiol(-) in liver microsomes from subjects with the UGT1A1*28 variant. Cancer Epidemiol. Biomarkers Prev., 2004, 13(1), 102-109.
28. Meyerhardt, J.A.; Kwok, A.; Ratain, M.J.; McGovren, J.P.; Fuchs, C.S. Relationship of baseline serum bilirubin to efficacy and toxicity of single-agent irinotecan in patients with metastatic colorectal cancer. J. Clin. Oncol., 2004, 22(8), 1439-1446.
29. Parodi, L.; Pickering, E.; Cisar, L.A.; Lee, D.; Soufi-Mahjoubi, R. Utility of Pretreatment Bilirubin Level and UGT1A1 Polymorphisms in Multivariate Predictive Models of Neutropenia Associated with Irinotecan Treatment in Previously Untreated Patients with Colorectal Cancer. Arch Drug Inf., 2008, 1(3), 97-106.
30. Kweekel, D.; Guchelaar, H.J.; Gelderblom, H. Clinical and pharmacogenetic factors associated with irinotecan toxicity. Cancer Treat. Rev., 2008, 34(7), 656-669.
31. Fuchs, C.S.; Marshall, J.; Mitchell, E.; Wierzbicki, R.; Ganju, V.; Jeffery, M.; Schulz, J.; Richards, D.; Soufi-Mahjoubi, R.; Wang, B.; Barrueco, J. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study. J. Clin. Oncol., 2007, 25(30), 4779-4786.
32. Hu, Z.Y.; Yu, Q.; Zhao, Y.S. Dose-dependent association between UGT1A1*28 polymorphism and irinotecan-induced diarrhoea: a meta-analysis. Eur. J. Cancer, 2010, 46(10), 1856-1865.
33. Mathijssen, R.H.; van Alphen, R.J.; Verweij, J.; Loos, W.J.; Nooter, K.; Stoter, G.; Sparreboom, A. Clinical pharmacokinetics and metabolism of irinotecan (CPT-11). Clin. Cancer Res., 2001, 7(8), 2182-2194.